SMARCA4/BRG1-deficient NSCLC: a case report and literature review

Authors

  • He Zhang Department of Respiratory and Critical Care Medicine, Yijishan Hospital, The first Affiliated Hospital of Wannan Medical College, Wuhu, China
  • Xiong-wen Tu Department of Respiratory and Critical Care Medicine, Yijishan Hospital, The first Affiliated Hospital of Wannan Medical College, Wuhu, China
  • Yu-qing Wei Department of Respiratory and Critical Care Medicine, Yijishan Hospital, The first Affiliated Hospital of Wannan Medical College, Wuhu, China
  • Zheng-zheng Ni Department of Thoracic Surgery, Yijishan Hospital, The first Affiliated Hospital of Wannan Medical College, Wuhu, China
  • Liang Cheng Department of Medical Imaging, Yijishan Hospital, The first Affiliated Hospital of Wannan Medical College, Wuhu, China
  • Juan Wu Department of Pathophysiology, Wannan Medical College, Wuhu, China

DOI:

https://doi.org/10.47391/JPMA.22492

Keywords:

NSCLC, SMARCA4-deficient, Treatment, Prognosis

Abstract

Patients with non-small cell lung cancer (NSCLC) deficient in SMARCA4 (SMARCA4-dNSCLC) are commonly diagnosed at advanced stages with a poor prognosis. Although immune checkpoint inhibitors (ICIs) combined with platinum-based chemotherapy regimens are widely used, their efficacy in SMARCA4-dNSCLC patients remains suboptimal. Herein, we present the case of a SMARCA4-dNSCLC patient treated at Yijishan Hospital on January 18, 2023. Following our comprehensive treatment, our patient's general condition and quality of life (QOL) have remained satisfactory, and there has been no disease progression to date.

Keywords: NSCLC, SMARCA4-deficient, Treatment, Prognosis.

Published

2025-09-25

How to Cite

He Zhang, Xiong-wen Tu, Yu-qing Wei, Zheng-zheng Ni, Liang Cheng, & Wu, J. (2025). SMARCA4/BRG1-deficient NSCLC: a case report and literature review. Journal of the Pakistan Medical Association, 75(10), 1621–1624. https://doi.org/10.47391/JPMA.22492

Issue

Section

CASE REPORT